Unknown PHASE4 INTERVENTIONAL 2-arm NCT01558310

A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis

A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis

Sponsor: Janssen Services, LLC

Conditions Plaque Psoriasis Scalp Psoriasis

Interventions Placebo Ustekinumab

Updated 6 times since 2017 Last updated: Jul 17, 2012 Started: Aug 31, 2012 Primary completion: Oct 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01558310, this PHASE4 trial focuses on Plaque Psoriasis and Scalp Psoriasis and remains ongoing. Sponsored by Janssen Services, LLC, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE4

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Services, LLC
Paul Steven Yamauchi, MD, PhD

Data source: Yamauchi, Paul Steven, M.D., Ph.D.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Santa Monica, United States